Tislelizumab (Tevimbra / Baize'an)
A PD-1 checkpoint inhibitor immunotherapy for advanced esophageal, gastric, lung, and liver cancers.
What is Tislelizumab?
What it targets
The PD-1 checkpoint on T-cells. By blocking this interaction between PD-1 and cancer-expressed PD-L1, tislelizumab restores anti-tumor immune activity.
Who it may help
Patients with advanced, unresectable, or metastatic esophageal, gastric, lung, or hepatocellular carcinoma whose tumors express PD-L1 and who meet eligibility criteria.
Why testing matters
PD-L1 expression testing determines eligibility and helps predict response. Biomarker-guided treatment selection optimizes benefit and minimizes unnecessary exposure.
Which cancers can Tislelizumab treat?
Tislelizumab is FDA-approved or clinically used in the following cancers where specific biomarker expression meets treatment criteria.
| Esophageal Squamous Cell Carcinoma (ESCC) | FDA-approved as monotherapy after prior chemotherapy (RATIONALE-302). Also approved with chemotherapy in some regions for first-line metastatic or unresectable disease. |
| Gastric and GEJ Adenocarcinoma | FDA-approved in combination with chemotherapy as first-line treatment for unresectable/metastatic disease with PD-L1 expression (RATIONALE-305). |
| Non-Small Cell Lung Cancer (NSCLC) | NMPA-approved in China for first-line squamous NSCLC with chemotherapy and non-squamous NSCLC in selected patients. Under study globally. |
| Hepatocellular Carcinoma (HCC) | NMPA conditional approval in China for HCC after prior systemic therapy. Under active clinical investigation in first-line and combination settings. |
| Other Cancers | In China, approved or studied for Hodgkin lymphoma, urothelial carcinoma, small cell lung cancer, and other solid tumors depending on regulatory status. |
Are you eligible for Tislelizumab?
Eligibility depends on cancer type, PD-L1 status, prior treatments, and organ function. Your oncologist will assess whether Tislelizumab is right for you.
- Confirmed diagnosis and PD-L1 testing showing sufficient PD-L1 expression (requirements vary by indication).
- Unresectable, locally advanced, metastatic, or recurrent disease in an FDA-approved or medically appropriate indication.
- Adequate liver function (transaminases within limits, no decompensated cirrhosis).
- Adequate kidney function (eGFR typically >30 mL/min).
- No active or untreated central nervous system metastases (treated brain mets may be acceptable).
- No active autoimmune disease or uncontrolled infection; adequate immune status.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ability to care for self with minimal assistance).
- Not pregnant or breastfeeding; effective contraception if of childbearing potential.
How does Tislelizumab work?
- Blocking the PD-1 checkpoint
- Unleashing immune cells
- Enhanced T-cell activity
- Sustained anti-tumor effect
Tislelizumab has a slower dissociation rate from PD-1 (50-100 times slower than some competitors), theoretically providing more sustained checkpoint blockade.
Tests required before starting Tislelizumab
These tests confirm eligibility, establish baselines, and guide monitoring during treatment.
| Tumour Biopsy and Histopathology | Confirms cancer type and stage. Essential for diagnosis and treatment planning. |
| PD-L1 Expression Testing | Determines tumour area positivity (TAP) or combined positive score (CPS). Required for eligibility and prognostic assessment. |
| Molecular Testing or NGS | Tests for EGFR, ALK, ROS1, BRAF, KRAS mutations (especially in lung cancer) to guide treatment sequencing. |
| Complete Blood Count (CBC) | Baseline blood counts and haemoglobin. Monitored during treatment for immune-related cytopaenias. |
| Liver Function Tests (LFTs) | AST, ALT, bilirubin baseline. Immunotherapy can cause hepatitis; regular monitoring essential. |
| Kidney Function Tests | Creatinine and eGFR determine dose safety. Immunotherapy can cause nephritis requiring dose adjustment. |
| Thyroid Function | TSH and free T4 baseline. Checkpoint inhibitors commonly cause thyroid dysfunction. |
| Baseline Imaging | CT, PET-CT, or MRI to document disease extent and guide response assessment at 6-12 weeks. |
How is Tislelizumab given?
Tislelizumab is administered as an intravenous infusion in a hospital, cancer centre, or infusion clinic under medical supervision.
| Standard Dosage | 200 mg intravenous infusion once every 3 weeks. Total infusion volume depends on formulation. |
| First Infusion | Administered over 60 minutes. If tolerated well, subsequent infusions may be shortened to 30 minutes. |
| Treatment Schedule | Infusions continue every 21 days (3 weeks) until disease progression, unacceptable toxicity, or completion of planned treatment. |
| Missed Infusion | Contact your oncology team immediately. Do not attempt to 'catch up' — treatment will be rescheduled as soon as possible. |
| Duration of Treatment | Median treatment duration varies by indication. Most patients continue until disease progression. Some may receive extended maintenance. |
| Dose Modifications | No routine dose reduction. If severe immune-related adverse events occur, infusions may be withheld and steroids given. Resume once resolved. |
Clinical evidence and benefits
Tislelizumab has demonstrated meaningful survival benefits in multiple randomized trials across different cancer types.
| Esophageal Cancer (RATIONALE-302) | Median overall survival 8.6 months vs 6.3 months with chemotherapy; hazard ratio 0.70 showing 30% risk reduction in death. |
| Gastric/GEJ Cancer (RATIONALE-305) | Median overall survival 15.0 months vs 12.9 months with combination chemotherapy; benefit sustained at 3-year follow-up. |
| Lung Cancer Benefits (NSCLC) | First-line squamous NSCLC with chemotherapy shows improved survival. Non-squamous and later-line NSCLC also benefit in selected patients. |
| Biomarker-Guided Benefit | Greater survival benefit observed in patients with NOTCH1 mutations (ESCC) and PD-L1 high expression. Better outcomes in selected subgroups. |
| Quality of Life | Immunotherapy patients often report better symptom control and functional status than chemotherapy alone, with less severe alopecia and nausea. |
Individual responses vary. These represent published clinical trial data. Your outcome depends on cancer type, stage, biomarkers, and overall health.
Side effects of Tislelizumab
Checkpoint inhibitor side effects are typically immune-related, occurring when the immune system attacks normal organs. Most are manageable with monitoring and early intervention.
| Fatigue | Very common (40-60% of patients). Usually mild to moderate. Improve with rest, sleep hygiene, and gradual activity increase. |
| Decreased Appetite | Common during and after infusions. Eating smaller, frequent meals and nutritional support helps maintain weight. |
| Diarrhoea | Can range from mild to severe. Mild cases managed with dietary changes; severe cases require steroids or treatment pause. |
| Rash or Skin Reactions | Itching, rash, or hives occur in 20-30% of patients. Topical treatments and antihistamines help; severe cases need steroids. |
| Cough | Can indicate immune-related pneumonitis (lung inflammation). Report new or worsening cough to your oncologist immediately. |
| Thyroid Dysfunction | Hypothyroidism (low thyroid) common; hyperthyroidism also occurs. Monitored by TSH; managed with thyroid replacement if needed. |
| Nausea and Vomiting | Mild in most cases; more common with combination chemotherapy. Anti-nausea medications available. |
| Headache or Dizziness | Generally mild and transient. Severe headache with vision changes requires urgent evaluation for immune-related neurological effects. |
Contact your doctor immediately if you develop:
- Severe or persistent diarrhoea (more than 4 stools/day) with abdominal pain or blood in stool.
- Yellowing of skin or eyes, dark urine, or severe right upper abdominal pain (signs of liver inflammation).
- New or worsening shortness of breath, chest pain, or persistent cough (signs of pneumonitis).
- Severe rash, blistering, peeling skin, or mouth ulcers.
- Weakness, numbness, vision changes, or difficulty speaking (neurological symptoms).
- Rapid heartbeat, chest pain, fainting, or leg swelling (cardiac or clotting signs).
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medicines, supplements, and herbal products you take.
- Autoimmune disease (lupus, rheumatoid arthritis, inflammatory bowel disease) may worsen on checkpoint inhibitors.
- Organ transplant recipients should discuss with oncologist; immunotherapy may trigger rejection.
- Hepatitis B, hepatitis C, HIV, or tuberculosis require careful monitoring and may influence treatment eligibility.
- Immunosuppressive drugs (methotrexate, azathioprine) may reduce efficacy; discuss adjustment with your doctors.
- Live vaccines (MMR, varicella, rotavirus) should be avoided during Tislelizumab; inactivated vaccines may be less effective.
- Pregnancy: Tislelizumab may cause foetal harm. Effective contraception required. If pregnancy planned, discuss with oncologist before starting.
- Breastfeeding: Unknown if Tislelizumab passes into breast milk. Not recommended during treatment.
Tislelizumab combination treatments
Tislelizumab is used alone in some settings and combined with chemotherapy in others, depending on cancer type and treatment line.
| Tislelizumab + Chemotherapy (ESCC) | Some first-line settings and trial data support combination approach, particularly in PD-L1-positive disease. Improves survival vs chemotherapy alone. |
| Tislelizumab + Chemotherapy (Gastric/GEJ) | FDA-approved first-line combination with fluoropyrimidine and platinum agents. Median OS 15.0 months, significantly better than chemotherapy. |
| Tislelizumab Monotherapy | ESCC after prior chemotherapy (FDA-approved). Some HCC and NSCLC patients receive monotherapy as later-line treatment. |
| Sequential Therapy Strategy | If Tislelizumab fails or is not tolerated, next-line options may include chemotherapy, targeted therapy, or other immunotherapy combinations. |
If Tislelizumab stops working
Resistance can develop through multiple mechanisms. Understanding why helps guide next treatment options.
| Primary Resistance (No Initial Response) | Some patients never respond. Causes include low PD-L1, high tumour mutational burden, or immunosuppressive microenvironment. |
| Secondary Resistance (Loss of Response) | Cancer evades immune attack through tumour remodeling, loss of antigen, or increased immunosuppression. Requires repeat imaging and testing. |
| Next-Line Options | Chemotherapy, targeted therapy (if driver mutations present), other checkpoint inhibitors, anti-angiogenic therapy, or clinical trials for novel combinations. |
| Biomarker Reassessment | Repeat biopsy and molecular testing (NGS, TMB, MSI) may identify resistance mechanisms and guide treatment switching. |
Cost of Tislelizumab by country
Tislelizumab pricing varies significantly by region and whether purchased under brand name or through government programs.
| China | Pricing reduced from $1,657/100mg to approximately $178/100mg following government negotiations (89% reduction by 2024). Some patients access via national insurance programs. |
| USA | FDA-approved Tevimbra priced at approximately $1,587/100mg. Patient assistance programs available through BeiGene. Insurance coverage varies. |
| Europe | EMA-approved Tevimbra. National insurance coverage varies by country. Some healthcare systems provide subsidized access. |
| India | Available through named patient supply (NPS) with valid prescription and DCGI import permit. Imported product cost varies; enquire through accredited suppliers. |
Availability of Tislelizumab globally
Regulatory approval status and commercial availability differ across countries. Verify status in your location before treatment planning.
USA
FDA-approved as Tevimbra (March 2024 for ESCC monotherapy; December 2024 for gastric/GEJ with chemotherapy). Available at US hospitals and cancer centres.
Europe
EMA conditional marketing authorization (September 2023) for ESCC monotherapy. Available in select European countries; availability varies by national health system.
China
NMPA-approved as Baize'an since 2019 for multiple indications including ESCC, NSCLC, HCC, and others. Widely available across Chinese hospitals and cancer centres.
India
Available through named patient supply (NPS) of imported Tevimbra. Requires valid prescription and DCGI Form 12A import permit. Access through accredited pharmaceutical distributors.
Other Regions
Approval status varies. Southeast Asia, Australia, and other countries may have different regulatory status. Check local regulatory authority for current approval status.
Tislelizumab in current clinical trials
Multiple trials are evaluating Tislelizumab in new indications, combinations, and patient populations to expand treatment options.
| RATIONALE Series Trials (Completed/Ongoing) | RATIONALE-302 (ESCC), RATIONALE-305 (gastric/GEJ), RATIONALE-312 (small cell lung cancer), and others defined the role of Tislelizumab in major cancers. |
| Combination Trials | Ongoing studies combine Tislelizumab with chemotherapy, anti-angiogenic agents, targeted drugs, and other immunotherapies in various cancers. |
| Biomarker and Patient Selection | Studies identify which biomarkers (NOTCH1, TMB, MSI) predict response better, allowing personalized treatment selection. |
| Clinical Trial Access | Patients whose cancer has progressed after standard treatment may be eligible for trials. Ask your oncologist about trial options in your region. |
Your treatment journey with Tislelizumab
Diagnosis and Molecular Testing
Pre-Treatment Evaluation
First Infusion and Monitoring
Early Response Assessment (6-12 weeks)
Ongoing Monitoring and Symptom Management
Treatment Decisions at Milestones
Questions to ask your oncologist about Tislelizumab
- Is Tislelizumab appropriate for my specific cancer type and stage?
- Do I have sufficient PD-L1 expression to benefit from Tislelizumab?
- What is the realistic goal of Tislelizumab for me: cure, remission, or extended survival?
- What side effects are most likely, and how will they be managed?
- How often will I need blood work and imaging during treatment?
- Can I take other medications, supplements, or herbal products with Tislelizumab?
- What happens if Tislelizumab doesn't work or stops working?
- What is the total cost, and what financial support is available?
How CancerFax supports Tislelizumab patients
CancerFax helps patients understand Tislelizumab eligibility, mechanism, side effects, and access pathways across India, China, and international centres.
| Report and PD-L1 Review | Upload your pathology and molecular reports. Our team reviews and explains your PD-L1 result, biomarker status, and what this means for Tislelizumab suitability. |
| Specialist Connection | We connect patients with oncologists experienced in PD-1 immunotherapy across India, China, and other countries. Specialist review accelerates diagnosis and treatment planning. |
| Second Opinion Support | If uncertain about Tislelizumab vs. other options, we arrange second opinions from leading cancer specialists in your indication. |
| Access and Affordability | For patients in India, we help navigate named patient supply (NPS) processes, understand cost, and identify legitimate sourcing channels. |
| International Treatment Coordination | Patients seeking Tislelizumab access in China, Singapore, or other countries benefit from CancerFax coordination of hospital partnerships and travel logistics. |
| Side Effect Management | We provide guidance on monitoring for immune-related side effects and help patients communicate urgent symptoms to their treatment team. |
Frequently asked questions about Tislelizumab
Common questions from patients and caregivers
Tislelizumab is an anti-PD-1 immunotherapy that works differently from chemotherapy. Instead of directly killing cancer cells, it blocks PD-1 checkpoint on immune cells, allowing your own T-cells to recognize and attack cancer. This targeted approach often causes fewer side effects than chemotherapy, such as less hair loss and nausea.
Response varies by cancer type and individual. In esophageal cancer trials, median survival improvements were observed within months. Initial imaging to assess response is typically done at 6-12 weeks. Your oncologist will monitor blood tests and scans to track how your cancer is responding.
PD-L1 testing checks if your cancer cells express the PD-L1 protein. Tislelizumab works best when this protein is present (especially at higher levels). Your pathology report shows PD-L1 status, which helps your oncologist decide if Tislelizumab is the right choice for you.
Tislelizumab can be combined with chemotherapy in many cancers and may interact with immunosuppressive drugs. Tell your oncologist and pharmacist about all medicines, supplements, and herbal products you take. Certain interactions may require dose adjustments or monitoring.
Immune-related side effects can occur as your immune system attacks normal organs. Contact your doctor immediately if you develop severe diarrhea, yellowing of the skin, shortness of breath, chest pain, severe rash, or neurological symptoms like weakness or vision changes.
Tislelizumab is available in India through named patient supply (NPS) under the brand name Tevimbra. Patients can import it with a valid prescription and import permit from the DCGI. CancerFax can help patients understand access pathways and cost implications.
Tislelizumab can control advanced cancer and extend survival, but it is not a cure. Treatment goals are to slow disease progression, extend survival, and improve quality of life. Your oncologist will discuss realistic outcomes based on your specific cancer type and stage.